Placebo to match ly3298176 injection
Sponsors
Eli Lilly & Co.
Conditions
ObesityOverweight
Phase 3
I8F-MC-GPIJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity
Active, not recruitingCTIS2022-501744-15-00
Start: 2023-01-23Target: 3725Updated: 2025-12-16
I8F-MC-GPIX: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)
Active, not recruitingCTIS2023-507655-30-00
Start: 2024-09-27Target: 45Updated: 2025-11-07